10:14 AM EDT, 10/08/2025 (MT Newswires) -- Nexalin Technology ( NXL ) shares rose 68% in recent Wednesday trading after the company said data from a peer-reviewed trial evaluating its 15 milliamp Gen-2 Nexalin DIFSTM device demonstrated "statistically significant" cognitive gains in patients with mild Alzheimer's disease.

Patients treated with the device showed a "significant" improvement in Mini-Mental State Examination and Montreal Cognitive Assessment scores compared with baseline measurements, the company said Wednesday in a statement.

No adverse events were reported during the treatment period, "reinforcing the safety and tolerability" of the technology, the company said.

The results support plans to expand treatment indications with international regulatory agencies, including the US Food and Drug Administration, the company said.

Price: 1.58, Change: +0.64, Percent Change: +67.87